Daegu’s FIX 2025 Expo Positions City as Global AI Innovation Hub
Daegu’s Strategic Pivot to AI-Driven Industry The Future Innovation Tech Expo (FIX) 2025, scheduled for October in Daegu, South Korea,…
Daegu’s Strategic Pivot to AI-Driven Industry The Future Innovation Tech Expo (FIX) 2025, scheduled for October in Daegu, South Korea,…
** In a landmark decision, the FDA has approved the first oral GLP-1 medication for reducing cardiovascular risk. The approval for Novo Nordisk’s Rybelsus is based on trial data showing a significant reduction in major adverse cardiac events for adults with type 2 diabetes, even without a prior history of heart attack or stroke. **CONTENT:**
Turning Concrete from Carbon Emitter to Carbon Sponge At the University of Pennsylvania’s Polyhedral Structures Laboratory, researchers are flipping the…
The New Frontier of Automated Cancer Screening In what represents a paradigm shift for medical diagnostics, the Galleri multi-cancer early…
A New Era in Permanent Data Preservation At the recent 2025 Open Compute Project Global Summit, Cerabyte unveiled what could…
From “Roughly Here” to “Exactly Here”: The New Era of Smartwatch Positioning For decades, smartwatch GPS has been a story…
The Silent Revolution in Energy Storage While solar panels and wind turbines capture public attention, a quieter revolution is unfolding…
Groundbreaking Engine Achieves Record Temperatures at Sub-Cellular Scale In a remarkable fusion of quantum mechanics and thermodynamics, researchers have engineered…
Breakthrough in Sustainable Chemistry In a significant advancement for green chemistry, researchers have developed a novel gold-perovskite catalyst that dramatically…
Note: Featured image is for illustrative purposes only and does not represent any specific product, service, or entity mentioned in…